CDS2 and neoplasm: In vitro exposure of LLC or B16-F10 tumor cells to Cds2 vMO does not alter proliferation rates, suggesting the reduced tumor growth rates we note in our in vivo vMO studies are not the result of inhibitory effects on the tumor cells themselves (Supplementary Figs. 10E and 11A).